Clinical Pharmacology & Therapeutics · 2001 · 104 citations · 11 references
MedicinePharmacologyToxicologyPharmaceutical ToxicologyPharmacogeneticsPharmacogenomicsCytochrome P450 EnzymesCytochrome P450 InteractionsCytochrome P450-mediated MetabolismDrug DispositionDrug Half-lifeDrug Metabolism GeneticsCyp2c19 Drug MetabolismCyp2c19 GenotypeCyp2c19 PharmacogeneticsCyp2c9 GenotypingCytochrome P450 GenotypingDrug Elimination Half-lifePhenytoin TherapySeizures
A 31-year-old woman who had a severe head injury was treated with oral phenytoin (100 mg 3 times a day) to prevent posttraumatic seizures. On day 10 of phenytoin treatment, 3 hours after the morning dose, the patient manifested neurologic signs compatible with phenytoin intoxication. Thus drug serum concentrations were monitored daily for 12 days. The elimination half-life was 103 hours, namely, about 5 times longer than the mean value generally quoted (22 hours). In the absence of any acquired predisposing factor for phenytoin toxicity, genetic mutations in the cytochrome P450 (CYP) enzymes responsible for phenytoin metabolism (CYP2C9 and CYP2C19) were suspected. Genotyping revealed that the patient was homozygous for the CYP2C9*3 allele (CYP2C9*3/*3) and heterozygous for the CYP2C19*2 allele (CYP2C19*1/*2). In view of the markedly reduced metabolic activity of CYP2C*3 in comparison with the wild-type enzyme (about one fifth) and of the minor role of CYP2C19 in phenytoin metabolism, it is likely that CYP2C9*3 mutation was largely responsible for drug overdose.
11
The role of the CFP2C9-Leu 359 allelic variant in the tolbutamide polymorphism
Theresa H. Sullivan-Klose, Burhan I. Ghanayem, Douglas A. Bell et al. · Pharmacogenetics · 1996 · 587 citations
Medicine, Genetics, Pharmacology +17
Genetic association between sensitivity to warfarin and expression of CYP2C9*3
Daniel J. Steward, Robert L. Haining, Kirk R. Henne et al. · Pharmacogenetics · 1997 · 308 citations